The weighed core symptom scale and prediction of ADHD in adults - objective measures of remission and response to treatment with methylphenidate

Hanna Edebol, Lars Helldin, Torsten Norlander, Hanna Edebol, Lars Helldin, Torsten Norlander

Abstract

Objective: Two measures of the response rate and the optimal treatment response for adult ADHD were evaluated using methylphenidate. The hypotheses were that Prediction of ADHD (PADHD) defines remission, the Weighed Core Symptom (WCS) scale registers direct effects of medication and that WCS may indicate the optimal dose level during titration.

Design: PADHD and WCS were analyzed at baseline and after intake of low doses of either short-acting or modified-release formulations of methylphenidate, MPH (Study I), during titration with modified-release formulations of MPH (18/27, 36, 54, 72 mg) and at three months follow-up (Study II).

Patients: Study I consisted of 63 participants (32 females) and Study II consisted of 10 participants (6 females) diagnosed with ADHD and who was to start with treatment.

Outcome measures: Prediction of ADHD (PADHD) indicates the occurrence of ADHD (No, Yes) and the Weighed Core Symptom scale (WCS) quantifies ADHD from 0 to 100 (max-min).

Results: The number of clinical cases of ADHD decreased after methylphenidate treatment according to PADHD. WCS increased (p < 0.001) from 9.75 (SD = 12.27) to 47.50 (SD = 29.75) with about 10 mg of methylphenidate (N = 63). During titration, symptoms improved after 18/27 mg and 36 mg of methylphenidate and baseline-follow up comparisons showed WCS increments (p = 0.005) from 31.00 (N = 10, SD = 26.85) to 69.00 (N = 10, SD = 22.34).

Conclusions: PADHD defined remission and WCS measured therapeutic effects of methylphenidate in adult ADHD.

Keywords: ADHD.; Objective measures; Prediction of ADHD; Weighed Core Symptom scale; remission.

References

    1. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder.Remision.recovery., relapse and recurrence. . Arch Gen Psychiatry. 1999; 48:851–5.
    1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United Sates: results from the national comorbidity survey replication. Am J Psychiatry . 2006.;163:716–23.
    1. Diagnostic and Statistical Manual of Mental Disorders 4th ed Washington DC. American Psychiatric Association. 2000
    1. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc. 2005;3:5.
    1. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The Eu-ropean Network Adult ADHD. BMC Psychiatry. 2010;10:67.
    1. Kelsey DK, Summer CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder. including assessment of evening and morning behavior: a double-bind.placebo-controlled trial. Pediatrics. 2004;114:1–8.
    1. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775–82.
    1. Ramos-Quiroga A, Casas M. Achieving remission as a routine goal of pharmacotherapy in attention-deficit hy-peractivity disorder. CNS Drugs. 2011;25:17–36.
    1. Hasson R, Goldenring Fine J. Gender differences among children with ADHD on continuous performance tests: a meta-analytic review. J Atten Disord. 2012;16:190–8.
    1. Retz W, Rösler M, Ose C, et al. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized pla-cebo-controlled multi-centre study with extended-release methylphenidate. World J Biol Psychiatry. 2012;13:48–59.
    1. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomized placebo-controlled 24-week. study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychol Clin Neurosci. 2009;259:120–9.
    1. Spencer T, Biederman J, Wilens T, et al. A large double-blind randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456–63.
    1. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field?. Clin Ther. 2006;28:1892–908.
    1. Swanson J. SNAP-IV scale Irvine California University of California Irvine Child. Development Center. 1995
    1. DuPaul G, Reid R, Power T, Anastopoulos A. ADHD Rating Scale-IV: checklists. norms and clinical inter-pretations. New ork. 1998
    1. Guy W. ECDEU: Assessment Manual for Psychopharmacology Revised Rockville MD. US Department of Health Education and Welfare. 1976
    1. Edebol H, Helldin L, Norlander T. Measuring adult Attention Deficit Hyperactivity Disorder with the Quantified Behavior Test Plus. Psychol J. 2013;2(1):48–6.
    1. Edebol H, Helldin L, Norlander T. Measuring adult attention deficit hyperactivity disorder with the quantified behaviour test plus. Psychol J. 2013;2(1):48–62.
    1. QbTech AB. QbTest Plus Clinical Manual. Gothenburg Sweden. 2010
    1. QbTech AB. QbTest Plus Technical Manual. Gothenburg Sweden. 2010
    1. QbTech AB. QbTest Plus Operational Manual. Gothenburg Sweden. 2010
    1. Kessler CR, Adler L, Ames M, et al. The world health organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35:245–56.
    1. Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885–90.
    1. Wender PH. Wender AQCC (Adult-Childhood Characteristics) scale. Psychopharmacol Bull. 1985;21:927–8.
    1. Conners CK, Erhardt D, Sparrow E. Adult ADHD rating scales: Technical manual. Toronto: Multi-Health Systems. 1999

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj